Todas las categorías
| Product Name | Descripción | Action |
|---|---|---|
| Cetuximab,Erbitux,EGFR,IMC-C225,Anticorpo monoclonal anti-EGFR,Anticorpo quimérico IgG1,Anticorpo biológico de oncología /Anticorpo contra el cáncer de colon y recto /Anticorpo contra el cáncer de cabeza y cuello,número CAS205923-56-4 | Trade Name : Erbitux Target : EGFR Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 650(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Aflibercept | Trade Name : Eylea Target : VEGF/PlGF Molecular Type : Fusion Protein Sales in 2025 (Millions of USD) : 7770(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Trastuzumab Emtansina, Kadcyla, Her2, T-DM1, Ado-trastuzumab emtansina, ADC dirigido a HER2, Microtubule inhibidor conjugado, ADC de enlace no separable, ADC maytansinoide, ADC de segunda generación | Trade Name : Kadcyla Target : Her2 Molecular Type : ADC Sales in 2025 (Millions of USD) : 2000~2200(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Trastuzumab Deruxtecan,Enhertu,Her2,DS-8201a,Fam-trastuzumab deruxtecan-nxki,ADC de tercera generación,ADC dirigido a HER2,conjugado de inhibidor de la topoisomerasa I,no CAS 1826843-81-5 | Trade Name : Enhertu Target : Her2 Molecular Type : ADC Sales in 2025 (Millions of USD) : 4500~5000(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Trastuzumab, Herceptin, Her2, Terapia dirigida a HER2, Anticorpo monoclonal anti-HER2, Anticorpo biológico en oncología / cáncer de mama, Anticorpo monoclonal para tumores con sobreexpresión de HER2, No CAS 180288-69-1 | Trade Name : Herceptin Target : Her2 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 3000 All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Nivolumab y berahialuronidasa alfa-pmph, Opdivo SC, Inyección subcutánea de Opdivo, Opdivo Qvantig, BMS-986251, Inhibidor de PD-1 subcutáneo, Producto combinado (901 y 932) | Trade Name : Opdivo Qvantig® Target : N/A Molecular Type : Combination Product (901 and 932) Sales in 2025 (Millions of USD) : N/A All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Nivolumab y relatlimab-rmbw, Opdualag Inyección, PD-1, LAG-3, BMS-986213, inhibidor dual PD-1 / LAG-3, inmunoterapia en combinación a dosis fijas, Combinación a dosis fijas (902 y 962) | Trade Name : Opdualag Target : PD-1, LAG-3 Molecular Type : Fixed-dose Combination (902 and 962) Sales in 2025 (Millions of USD) : 1000~1200(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get ... |
|
| Nivolumab, Opdivo, PD-1, BMS-936558, ONO-4538, Anti-PD-1, Inhibidor del punto de control inmune, Anticorpo monoclonal, Número CAS 946414-94-4 | Trade Name : Opdivo Target : PD-1 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 12000 All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
